Neuralink's Blindsight implant awaits regulatory green light, Musk says
Elon Musk claims the company's second brain-computer interface product is engineered and ready, pending approval from regulators to begin human trials for restoring vision to the blind.
Neuralink, the brain-computer interface venture founded by Elon Musk in 2016, has moved beyond its first commercial application and is preparing to launch a second product aimed at treating blindness. The company's initial implant, marketed as Telepathy, has already demonstrated its capability in human patients, who have used the device to control a computer cursor through thought alone and play games like World of Warcraft. Now Musk is signaling that Blindsight, the company's next offering, has cleared the engineering phase of development.
According to Musk, Blindsight will "enable even those who are completely blind or have never seen to see." He stated that the technology is "ready from an engineering standpoint" and is "just waiting on regulatory approval." The timeline for human trials remains uncertain, as the regulatory process could take months or longer before Neuralink can begin testing the implant in patients.
Neuralink's journey to this point began with the company's first human implant recipient in 2024. That initial patient demonstrated the fundamental capability of the technology by moving a cursor on a screen using only thought. Musk described the original Telepathy implant as enabling "high-speed communication with computers or humans simply by thinking," and predicted that "output bandwidth will vastly exceed the fastest human speed or typing in a few years."